Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

2.2K
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
2.2K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

957
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
957
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

497
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
497
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.2K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.2K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.1K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SMURF: soft-segmentation for single-cell reconstruction and topological analysis of spatial transcriptomic data.

Nature communications·2026
Same author

Unraveling anastomotic leak: biological mechanisms underlying intestinal healing after resection.

American journal of physiology. Gastrointestinal and liver physiology·2026
Same author

Soluble Thrombomodulin Links Viremia and Mortality During COVID-19: Results From the ACTIV-4a Trial.

Journal of the American Heart Association·2026
Same author

Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence.

Brain, behavior, & immunity - health·2026
Same author

Building Australia's non-animal technologies ecosystem: a national cross-sector mapping and strategic insights from the non-animal technologies network (NAT-Net).

Frontiers in toxicology·2026
Same author

A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer.

Science advances·2026

Related Experiment Video

Updated: Jan 28, 2026

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K

PAI-1 augments mucosal damage in colitis.

Gerard E Kaiko1,2,3, Feidi Chen1, Chin-Wen Lai1

  • 1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Science Translational Medicine
|March 8, 2019
PubMed
Summary

Elevated plasminogen activator inhibitor-1 (PAI-1) in inflammatory bowel disease (IBD) correlates with active disease and poor response to anti-TNF therapy. Inhibiting PAI-1 reduces gut inflammation and damage.

More Related Videos

Murine Colitis Modeling using Dextran Sulfate Sodium DSS
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

51.0K
Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.7K

Related Experiment Videos

Last Updated: Jan 28, 2026

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

51.0K
Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

10.7K

Area of Science:

  • Gastroenterology
  • Immunology
  • Molecular Biology

Background:

  • Inflammatory bowel disease (IBD) lacks clear biomarkers for disease activity and treatment response.
  • Identifying novel therapeutic targets and patient stratification methods for IBD is crucial.

Purpose of the Study:

  • To identify key molecular pathways involved in IBD pathogenesis using transcriptome analysis.
  • To investigate the role of the coagulation pathway, specifically plasminogen activator inhibitor-1 (PAI-1), in IBD.

Main Methods:

  • Global transcriptome analysis of colon biopsies from IBD patients and controls.
  • Gene-network analysis across 14 independent cohorts (1800 biopsies).
  • Functional studies in mice to assess the role of PAI-1 and tissue plasminogen activator (tPA) in intestinal injury and inflammation.

Main Results:

  • The coagulation gene pathway was significantly enriched in IBD patients.
  • PAI-1 expression was elevated in active IBD and in patients unresponsive to anti-tumor necrosis factor (TNF) therapy.
  • PAI-1 exacerbates intestinal damage by inhibiting tPA-mediated activation of TGF-β; PAI-1 inhibition reduced damage and inflammation in mice.

Conclusions:

  • An immune-coagulation axis exists in IBD, with PAI-1 as a key mediator.
  • Elevated PAI-1 may indicate more severe IBD and predict poor response to anti-TNF therapy.
  • PAI-1 inhibition presents a potential therapeutic strategy for IBD.